Economic impact of antidepressant treatment duration in naturalistic conditions

Acta Psychiatrica Scandinavica

Volumn 127, Issue 5, 2013, Pages 365-372

  Tournier, M ^a,b,c   Crott, R ^b   Gaudron, Y ^b   Verdoux, H ^a,b,c  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSERM   (France)

^c CENTRE HOSPITALIER CHARLES PERRENS   (France)

Author keywords

Antidepressant; Effectiveness; Health insurance database; Practice guidelines; Treatment duration

Indexed keywords

ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; DATA BASE; DEPRESSION; DISEASE REGISTRY; ECONOMIC ASPECT; FEMALE; HEALTH CARE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER; DRUG COSTS; FEMALE; FRANCE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 84876487461     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12035     Document Type: Article

References (32)

1. Holma IA, Holma KM, Melartin TK, Rytsala HJ, Isometsa ET. A 5-year prospective study of predictors for disability pension among patients with major depressive disorder. Acta Psychiatr Scand 2012;125:325-334.
2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442.
3. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-1504.
4. Ustun TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004;184:386-392.
5. Wagner S, Doering B, Helmreich I, Lieb K, Tadic A. A meta-analysis of executive dysfunctions in unipolar major depressive disorder without psychotic symptoms and their changes during antidepressant treatment. Acta Psychiatr Scand 2012;125:281-292.
6. Anderson IM, Ferrier IN, Baldwin RC et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008;22:343-396.
7. Reid S, Barbui C. Long term treatment of depression with selective serotonin reuptake inhibitors and newer antidepressants. BMJ 2010;340:c1468.
8. Tournier M, Cougnard A, Boutouaba-Combe S, Verdoux H. [Duration of antidepressant drug treatment and its determinants in France]. Encephale 2011;37(Suppl 1):S36-S41.
9. Sanglier T, Saragoussi D, Milea D, Auray JP, Valuck RJ, Tournier M. Comparing antidepressant treatment patterns in older and younger adults: a claims database analysis. J Am Geriatr Soc 2011;59:1197-1205.
10. Tournier M, Moride Y, Crott R, Du Fort GG, Ducruet T. Economic impact of non-persistence to antidepressant therapy in the Quebec community-dwelling elderly population. J Affect Disord 2009;115:160-166.
11. Moride Y, Du Fort GG, Monette J et al. Suboptimal duration of antidepressant treatments in the older ambulatory population of Quebec: association with selected physician characteristics. J Am Geriatr Soc 2002;50:1365-1371.
12. Verdoux H, Cougnard A, Thiebaut A, Tournier M. Impact of duration of antidepressant treatment on the risk of occurrence of a new sequence of antidepressant treatment. Pharmacopsychiatry 2011;44:96-101.
13. Gardarsdottir H, Egberts TC, Stolker JJ, Heerdink ER. Duration of antidepressant drug treatment and its influence on risk of relapse/recurrence: immortal and neglected time bias. Am J Epidemiol 2009;170:280-285.
14. Gardarsdottir H, Van Geffen EC, Stolker JJ, Egberts TC, Heerdink ER. Does the length of the first antidepressant treatment episode influence risk and time to a second episode? J Clin Psychopharmacol 2009;29:69-72.
15. Aikens JE, Kroenke K, Swindle RW, Eckert GJ. Nine-month predictors and outcomes of SSRI antidepressant continuation in primary care. Gen Hosp Psychiatry 2005;27:229-236.
16. Mitchell AJ, Vaze A, Rao S. Clinical diagnosis of depression in primary care: a meta-analysis. Lancet 2009;374:609-619.
17. Sewitch MJ, Blais R, Rahme E, Bexton B, Galarneau S. Receiving guideline-concordant pharmacotherapy for major depression: impact on ambulatory and inpatient health service use. Can J Psychiatry 2007;52:191-200.
18. Blais R, Partlova H, Lachaine J, Sewitch MJ. Is conformity to depression treatment guidelines associated with reduced health services costs? Pratiques et Organisation des Soins 2010;41:349-357.
19. Revicki DA, Simon GE, Chan K, Katon W, Heiligenstein J. Depression, health-related quality of life, and medical cost outcomes of receiving recommended levels of antidepressant treatment. J Fam Pract 1998;47:446-452.
20. Cully JA, Zimmer M, Khan MM, Petersen LA. Quality of depression care and its impact on health service use and mortality among veterans. Psychiatr Serv 2008;59:1399-1405.
21. Martin-Latry K, Begaud B. Pharmacoepidemiological research using French reimbursement databases: yes we can. Pharmacoepidemiol Drug Saf 2010;19:256-265.
22. WHO Collaborating Centre for Drug Statistics Methodology. About the ATC/DDD system. Oslo, Norway: Norwegian Institute of Public Health, 2007.
23. STATA CORP. Stata Statistical Software: Release 11. College Station TX, USA; StataCorp LP, 2009
24. Gibson TB, Jing Y, Smith Carls G et al. Cost burden of treatment resistance in patients with depression. Am J Manag Care 2010;16:370-377.
25. Cantrell CR, Eaddy MT, Shah MB, Regan TS, Sokol MC. Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes. Med Care 2006;44:300-303.
26. Bosmans JE, De Bruijne MC, De Boer MR, Van Hout H, Van Steenwijk P, Van Tulder MW. Health care costs of depression in primary care patients in The Netherlands. Fam Pract 2010;27:542-548.
27. Katon WJ, Walker EA. Medically unexplained symptoms in primary care. J Clin Psychiatry 1998;59(Suppl 20):15-21.
28. Barsky AJ, Delamater BA, Clancy SA, Antman EM, Ahern DK. Somatized psychiatric disorder presenting as palpitations. Arch Intern Med 1996;156:1102-1108.
29. Kirmayer LJ, Robbins JM, Dworkind M, Yaffe MJ. Somatization and the recognition of depression and anxiety in primary care. Am J Psychiatry 1993;150:734-741.
30. Barsky AJ, Orav EJ, Bates DW. Somatization increases medical utilization and costs independent of psychiatric and medical comorbidity. Arch Gen Psychiatry 2005;62:903-910.
31. Grolleau A, Cougnard A, Begaud B, Verdoux H. [Psychotropic drug use and correspondence with psychiatric diagnoses in the mental health in the general population survey]. Encephale 2008;34:352-359.
32. Grolleau A, Cougnard A, Begaud B, Verdoux H. Congruence between diagnosis of recurrent major depressive disorder and psychotropic treatment in the general population. Acta Psychiatr Scand 2008;117:20-27.